Parenteral Drugs (India) (NSE:PDPL) ROE % Adjusted to Book Value: Negative Equity% (As of Mar. 2022)


NSE:PDPL Parenteral Drugs (India) Ltd NSE:PDPL
4 GF Score
Price ₹2.90
View Full Analysis

What is Parenteral Drugs (India) ROE % Adjusted to Book Value?

Parenteral Drugs (India) NSE:PDPL 4 ROE % Adjusted to Book Value is Negative Equity% as of Mar. 2022. GuruFocus rates NSE:PDPL with a GF Score™ of 4/100.

Parenteral Drugs (India)'s ROE % for the quarter that ended in Mar. 2022 was Negative Equity. Parenteral Drugs (India)'s PB Ratio for the quarter that ended in Mar. 2022 was N/A. Parenteral Drugs (India)'s ROE % Adjusted to Book Value for the quarter that ended in Mar. 2022 was Negative Equity.

Parenteral Drugs (India) ROE % Adjusted to Book Value Related Terms

Parenteral Drugs (India) ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Parenteral Drugs (India)'s ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parenteral Drugs (India) ROE % Adjusted to Book Value Chart

Parenteral Drugs (India) Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Parenteral Drugs (India) Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 Negative Equity

NSE:PDPL vs ZTS, CTLT, VTRS: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Parenteral Drugs (India)'s ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parenteral Drugs (India) ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parenteral Drugs (India)'s ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Parenteral Drugs (India)'s ROE % Adjusted to Book Value falls into.


NSE:PDPL
4GF Score
Parenteral Drugs (India) Ltd NSE:PDPL
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parenteral Drugs (India) ROE % Adjusted to Book Value Calculation

Parenteral Drugs (India)'s ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Parenteral Drugs (India)'s ROE % Adjusted to Book Value for the quarter that ended in Mar. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=Negative Equity / N/A
=Negative Equity

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of Negative Equity% mean?
Parenteral Drugs (India) (NSE:PDPL) has a ROE % Adjusted to Book Value of Negative Equity% as of Mar. 2022. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Parenteral Drugs (India) and its competitors.
Is Parenteral Drugs (India)'s ROE % Adjusted to Book Value too high?
Parenteral Drugs (India)'s current ROE % Adjusted to Book Value is Negative Equity%. Overall, Parenteral Drugs (India) has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Parenteral Drugs (India)'s ROE % Adjusted to Book Value compare to ZTS and CTLT?
Parenteral Drugs (India)'s ROE % Adjusted to Book Value of Negative Equity% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Parenteral Drugs (India) and its competitors. Parenteral Drugs (India)'s current ROE % Adjusted to Book Value is Negative Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parenteral Drugs (India) stock overvalued right now?
Parenteral Drugs (India) (NSE:PDPL) has a current ROE % Adjusted to Book Value of Negative Equity%. The current ROE % Adjusted to Book Value is Negative Equity%. Parenteral Drugs (India)'s overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Parenteral Drugs (India) (NSE:PDPL), the current ROE % Adjusted to Book Value is Negative Equity% as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parenteral Drugs (India) Business Description

Address Navlakha Crossing, A. B. Road, Shree Ganesh Chambers, Indore, MP, IND, 452001
Parenteral Drugs (India) Ltd is a pharmaceutical company. It is principally engaged in manufacturing pharmaceutical preparations. The company manufactures products in categories like intravenous (IV) fluids, oncology, anesthesia, and export products. Its IV fluids products include carbohydrates and electrolytes, diuretics, dialysis, and irrigation solution, anti-infective and anti-fungal, and other pharmaceutical products.
4GF Score

Get the complete analysis for NSE:PDPL

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2.90
Price